This trial is evaluating whether EMB-01 will improve 3 primary outcomes, 11 secondary outcomes, and 1 other outcome in patients with Neoplasm Metastasis. Measurement will happen over the course of Screening up to follow-up (30 days after the last dose).
This trial requires 186 total participants across 2 different treatment groups
This trial involves 2 different treatments. EMB-01 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Neoplasm metastasis can be treated and cured by adjuvant chemotherapy, radiation therapy, or biotherapy; however, if metastatic dissemination arises from tumor cells of the primary neoplasm, the metastatic lesions are usually untreatable.
In a recent study, findings from this study indicate [prognosis and metastasis risk factors in oral neoplasm patients] that the stage of the disease is [the most important factor in determining metastasis risk].
Data from a recent study would suggest that serum CA19-9 is not an effective and specific tests for detecting the neoplasm metastasis in patients with pancreatic malignancy.
A variety of medications and procedures are used to treat neoplasm metastasis. They may include medications (e.g., chemotherapy) and procedures (e.g., surgical resection, radiotherapy, cryotherapy, and hormonal therapy) may be used to treat metastatic prostate cancer. However, there is no set treatment tailored to individual patients. A number of treatments used to treat metastatic prostate cancer are associated with improved outcomes (survival, time to progression).\n
The estimates in this study represent a moderate case mix of the total number of metastatic lung cancers diagnosed in the United States. The most common sites of primary tumor for metastatic lung tumors are the lung, the bronchus/bronchioloalveolar system, and other respiratory tracts.
Neoplasm metastasis can be present in many organs of the body, but in the present study most frequent metastatic sites were the liver and bone. Neoplasm metastasis was more common in women and in patients with higher TNM stage.
EMB-01 treatment is currently recommended in all patients with HNSCC. The majority of patients would benefit from EMB-01 therapy. However, for patients with small-volume disease, there is no clear benefit for EMB-01 treatment. Clinical trials with larger patient populations are essential to confirm the efficacy and safety profile of EMB-01.
A higher than expected percentage of metastatic tumors appears to result from heredity; this is an important finding for patients with cancer. There were no identifiable risk factors for metastasis in this small series. A larger, more comprehensive sample may help to identify predisposing alleles for neoplasm metastasis.
Emb-01 was found to be effective to promote an enhanced immune response against cancer cells especially when in conjunction with the use of radiation and chemotherapy. Findings from a recent study provides compelling evidence that the combination of emb-01 in combination therapy may prevent or alleviate tumor development and has the potential to be a valid adjuvant treatment for a range of cancers.
Neoplasm metastasis is an uncommon disease. The chances of neoplasm metastasis increases with the degree of resection or with the distance between the tumor and the primary site. Neoplasm metastasis should be considered in a patient presenting with an unusual course of disease.
Current treatment modalities are not successful in eliminating cancer cells that originate in other organs. A comprehensive understanding of the mechanism that controls the metastatic process is necessary for the discovery of specific and effective therapeutic strategies.
Emb-01 is a new anti-angiogenesis compound that has been safely implanted in a small group of people for short periods of time. However, when used on a larger population for an extended period, there may not be optimal dosage or timing of treatment, and the patient population for emb-01 is highly restricted. Although the safety of emb-01 has not yet been proven and there have only been small case numbers, the initial experience with emb-01 is excellent. In all cases, emb-01 has been well tolerated.